ClinicalTrials.gg
RecruitingNCT06316895Updated Mar 20, 2026

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

An observational study in Papillary Thyroid Cancer, sponsored by Chinese PLA General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Chinese PLA General Hospital · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,772
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Thyroid Cancer, Papillary with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Thyroid Cancer, Papillary · China.

Planned enrollment
Largest of 19
3,772 · median 541
Started
2024
with 9 others
Observational
19 of 40
15 open now
Primary completion
2027-04
later than 15 of 24 live
Registered
23rd of 40
by date
Lead sponsor
3 of 40
Chinese PLA General Hospital

Among the 40 studies in Thyroid Cancer, Papillary with a site in China, this one has the largest planned enrollment of the 19 observational ones that give a count, is one of 10 that started in 2024, is one of 19 observational ones, reaches primary completion later than 15 of the 24 other live ones, and was the 23rd registered.

Thyroid Cancer, Papillary

187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.

Browse Thyroid Cancer, Papillary studies →

Open to participants now

24 of the 40 studies in Thyroid Cancer, Papillary with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Thyroid Cancer, Papillary with a site in China, or all of them as a file.
02

Study summary

  1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma;
  2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of papillary thyroid carcinoma;
03

Conditions studied

  • Papillary Thyroid Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with low-risk papillary thyroid carcinoma who choose surgery or thermal ablation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients age between 18 and 80 year old, both sex
  2. papillary thyroid carcinoma confirmed by core-needle or fine-needle aspiration
  3. the largest diameter ≤2.0 cm
  4. no clinical or imaging evidences of extrathyroidal extension, lymph node and distant metastasis on ultrasound, nech and chest CT
  5. follow-up period ≥12 months,

Exclusion criteria

Exclusion Criteria:

  1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by
  2. history of neck radiation
  3. history of thyroid surgery
  4. coagulation disorder
  5. serious heart, respiratory, liver, or renal failure
  6. dysfunction of the vocal cord on the opposite side
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,772 participants (estimated)
Patient registry
No

Groups and cohorts

  • surgery group

    patients with low-risk papillary thyroid carcinoma who chose thyroid surgery

    Procedure: thyroid surgery

  • ablation group

    patients with low-risk papillary thyroid carcinoma who chose thermal ablation

    Procedure: ultrasound-guided thermal ablation

Interventions

  • Procedurethyroid surgery

    thyroid lobectomy

  • Procedureultrasound-guided thermal ablation

    radiofrequency ablation; microwave ablation or laser ablation

06

What researchers measure

Primary outcomes

  1. rate of disease progression

    cervical lymph node metastases, recurrent tumors and persistent tumors

    Time frame: more than 5 year

Secondary outcomes

  1. Rate of complications

    surgery or ablation complications

    Time frame: 1week

  2. Rate of tumor disappearance

    complete disappearance of ablated tumor on ultrasound and contrast-enhanced ultrasound

    Time frame: 2 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2024
First posted
Mar 19, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Apr 1, 2027
CompletionEst.
Dec 31, 2029
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06316895
Responsible party
Yu-kun Luo (Director, Head of Department of Ultrasound, Chinese PLA General Hospital) — Principal investigator
First posted
Mar 19, 2024
Start date
Apr 1, 2024
Primary completion
Apr 1, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 20, 2026

Study contacts

Lin Yan, MD
Contact
gemma-y@163.com
13811237313 ext. 86
Yukun Luo
study chair · Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion